(86 days)
Contour SE™ Microspheres may be used for the embolization of hypervascular tumors, including leiomyoma uteri, and arteriovenous malformations (AVMs).
Contour SET™ Microspheres may be used for the embolization of hypervascular tumors, including leiomyoma uteri, and arteriovenous malformations (AVMs).
The provided text is a summary of safety and effectiveness for a medical device (Contour SET™ Microspheres) and a letter from the FDA regarding its 510(k) premarket notification. This document outlines the general provisions, intended use, and substantial equivalence to predicate devices for the Contour SET™ Microspheres.
However, the document does not contain information about acceptance criteria, specific device performance metrics, detailed study designs (sample sizes for test/training sets, data provenance, expert qualifications for ground truth, adjudication methods, MRMC studies, or standalone algorithm performance), or the type of ground truth used, in the context that would be expected for a typical AI/ML device study.
Therefore, I cannot populate the table or answer the specific questions about acceptance criteria and study details as requested. The document focuses on regulatory approval based on substantial equivalence to existing devices and biocompatibility, not on a performance study against predefined acceptance criteria for a new AI/ML-driven device.
No information is available in the provided text to fulfill the request for a table of acceptance criteria and reported device performance, or the detailed study information regarding sample sizes, ground truth establishment, expert qualifications, or MRMC studies.
{0}------------------------------------------------
MAR 2 6 2004
Image /page/0/Picture/1 description: The image shows a sequence of handwritten alphanumeric characters. The sequence reads 'K034068' from left to right. The characters are written in a simple, slightly rough style, with some variations in line thickness.
Section 15
Summary of Safety and Effectiveness
| General Provisions | Trade Name: Contour SET™ MicrospheresClassification Name: Artificial Embolization Device |
|---|---|
| Name ofPredicateDevices | Contour SET™ Microspheres (K022427, K032707 & K032542)Contour™ Emboli PVA (K030966) |
| Classification | Class III |
| PerformanceStandards | Performance Standards have not been established by FDA under Section 514 ofthe Food, Drug and Cosmetic Act |
| Intended Useand DeviceDescription | Contour SET™ Microspheres may be used for the embolization of hypervasculartumors, including leiomyoma uteri, and arteriovenous malformations (AVMs). |
| Biocompatibility | No new materials have been introduced during this modification to the indicationsfor use statement as compared to the predicate devices. The predicate deviceshave been tested for biocompatibility per ISO 10993. All data demonstrate thisdevice is biocompatible for its intended use. |
| Summary ofSubstantialEquivalence | The Contour SET™ Microspheres have been tested and compared to the predicatedevice. All data gathered demonstrate this device as substantially equivalent. Nonew issues of safety or efficacy have been raised. Clinical data were collected in aprospective clinical study to support the safety and effectiveness of these devicesfor treatment of uterine fibroids. |
{1}------------------------------------------------
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
MAR 26 2004
Ms. Jennifer Bolton, RAC Senior Regulatory Affairs Specialist Boston Scientific Corporation One Boston Scientific Place NATICK MA 01760-1537
Re: K034068
Trade/Device Name: UAE Contour SE™ Microspheres Regulation Number: 21 CFR 870.3300 Regulation Name: Arterial embolization device Regulatory Class: III Product Code: 74 KRD and 85 NAJ Dated: December 30, 2003 Received: December 31, 2003
Dear Ms. Bolton:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination docs not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{2}------------------------------------------------
This letter will allow you to begin marketing your device as described in your Section 510(k) I mis lotter will and it your be FDA finding of substantial equivalence of your device to a legally promaticated predicated. " ceresults in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please If you dosite specific at Compliance at one of the following numbers, based on the regulation number at the top of the letter:
| 8xx.1xxx | (301) 594-4591 |
|---|---|
| 876.2xxx, 3xxx, 4xxx, 5xxx | (301) 594-4616 |
| 884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx | (301) 594-4616 |
| 892.2xxx, 3xxx, 4xxx, 5xxx | (301) 594-4654 |
| Other | (301) 594-4692 |
Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding Other or other to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Nancy C. brogden.
Nancy C. Brogdon Director, Division of Reproductive, Abdominal and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
Indications for Use
510(k) Number (if known): K034068
Device Name: Contour® SE™ Microspheres
Indications For Use: Contour SE™ Microspheres may be used for the embolization of hypervascular tumors, including leiomyoma uteri, and arteriovenous malformations (AVMs).
Prescription Use
(Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Nancy Choydon
(Division Sion Off) Division of Reproductive. And and Radiological Devices 510(k) Number
Page 1 of of
§ 870.3300 Vascular embolization device.
(a)
Identification. A vascular embolization device is an intravascular implant intended to control hemorrhaging due to aneurysms, certain types of tumors (e.g., nephroma, hepatoma, uterine fibroids), and arteriovenous malformations. This does not include cyanoacrylates and other embolic agents, which act by polymerization or precipitation. Embolization devices used in neurovascular applications are also not included in this classification, see § 882.5950 of this chapter.(b)
Classification. Class II (special controls.) The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices.” For availability of this guidance document, see § 870.1(e).